Citigroup Initiates Coverage On Bio-Techne with Neutral Rating, Announces $235 Price Target

Citigroup analyst Patrick Donnelly initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and a $235 price target.

Benzinga · 01/07/2020 12:01

Citigroup analyst Patrick Donnelly initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and a $235 price target.